Pharmacologic Modification of Radiation-Induced Late Normal Tissue Injury

  • John E. Moulder
  • Michael E. C. Robbins
  • Eric P. Cohen
  • John W. Hopewell
  • William F. Ward
Part of the Cancer Treatment and Research book series (CTAR, volume 93)


Classically, late radiation-induced normal tissue morbidity has been viewed as due solely to a delayed reduction in the number of surviving clonogens of either parenchymal [1] or vascular [2] target cell populations. These chronic late effects have been held to be inevitable, progressive, and untreatable [2]. In the classical model, the progressive and untreatable nature of late tissue damage follows from the assumption that the decline in clonogen number is due to mitotic cell death that results from genetic injury produced at the time of irradiation and irrevocably fixed in place within hours after irradiation. The long latent period for the expression of injury in tissues such as the kidney, lung, and spinal cord is explained by assuming that the target clonogenic cell population has a very long doubling time.


Radiation Injury Radiation Pneumonitis Compute Tomography Density Captopril Therapy Moist Desquamation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Withers HR, Peters LJ, Kogelnik HD. 1980. The pathobiology of late effects of irradiation. In Meyn RE, Withers HR, eds. Radiation Biology in Cancer Research. New York: Raven Press, pp. 439–448.Google Scholar
  2. 2.
    Rubin P, Casarett GW. 1968. Clinical Radiation Pathology. Philadelphia; W.B. Saunders.Google Scholar
  3. 3.
    Schultheiss TE, Stephens LC. 1992. Permanent radiation myelopathy. Br J Radiol 65:737–753.PubMedGoogle Scholar
  4. 4.
    Jaenke RS, Robbins MEC, Bywaters T, Whitehouse E, Rezvani M, Hopewell JW. 1993. Capillary endothelium: Target site of renal radiation injury. Lab Invest 68:396–405.PubMedGoogle Scholar
  5. 5.
    Cohen EP. 1995. Fibrosis causes progressive kidney failure. Med Hypotheses 45:459–462.PubMedGoogle Scholar
  6. 6.
    Michalowski AS. 1994. On radiation damage to normal tissues and its treatment II. Anti-inflammatory drugs. Acta Oncol 33:139–157.PubMedGoogle Scholar
  7. 7.
    Ward WF, Molteni A, Ts’ao CH, Kim YT, Hinz JM. 1992. Radiation pneumotoxicity in rats: Modification by inhibitors of angiotensin converting enzyme. Int J Radiat Oncol Biol Phys 22:623–625.PubMedGoogle Scholar
  8. 8.
    Robbins MEC, Hopewell JW. 1986. Physiological factors effecting renal radiation tolerance: A guide to the treatment of late effects. Br J Cancer 53:265–267.Google Scholar
  9. 9.
    Moulder JE, Fish BL, Cohen EP. 1993. Treatment of radiation nephropathy with ACE inhibitors. Int J Radiat Oncol Biol Phys 27: 93–99.PubMedGoogle Scholar
  10. 10.
    Cohen EP, Moulder JE, Fish BL, Hill P. 1994. Prophylaxis of experimental bone marrow transplant nephropathy. J Lab Clin Med 124:371–380.PubMedGoogle Scholar
  11. 11.
    Ward WF, Molteni A, Ts’ao C, Hinz JM. 1990. The effect of captopril on benign and malignant reactions in irradiated rat skin. Br J Radiol 63:349–354.PubMedGoogle Scholar
  12. 12.
    Moulder JE, Fish BL, Cohen EP, Bonsib SM. 1996. Angiotensin II receptor antagonists in the prevention of radiation nephropathy. Radiat Res 146:106–110.PubMedGoogle Scholar
  13. 13.
    Dion MW, Hussey DH, Osborne JW. 1989. The effect of pentoxifylline on early and late radiation injury following fractionated irradiation in C3H mice. Int J Radiat Oncol Biol Phys 17:101–107.PubMedGoogle Scholar
  14. 14.
    Hornsey S, Myers R, Jenkinson T. 1990. The reduction of radiation damage to the spinal cord by post-irradiation administration of vasoactive drugs. Int J Radiat Oncol Biol Phys 18:1437–1442.PubMedGoogle Scholar
  15. 15.
    Fike JR, Gobbel GT, Marton LJ, Seilhan TM. 1996. Radiation brain injury is reduced by the polyamine inhibitor OC-difluoromethylornithine. Radiat Res 138:99–106.Google Scholar
  16. 16.
    Ward WF, Kim YT, Molteni A, Solliday NH. 1988. Radiation-induced pulmonary endothelial dysfunction in rats: Modification by an inhibitor of angiotensin converting enzyme. Int J Radiat Oncol Biol Phys 15:135–140.PubMedGoogle Scholar
  17. 17.
    Chopra M, Scott N, McMurray J, McLay J, Bridges A, Smith WE, Belch JJF. 1989. Captopril: A free radical scavenger. Br J Clin Pharm 27:396–399.Google Scholar
  18. 18.
    Roberts NA, Robinson PA. 1985. Copper che-lates of antirheumatic and anti-inflammatory agents: Their Superoxide dismutase-like activity and stability. Br J Rheumatol 24:128–136.PubMedGoogle Scholar
  19. 19.
    Bauer H, Lametschwandtner A, Steiner M, Bauer HC. 1990. Influence of angiotensin converting enzyme inhibitor (captopril) on kidney epithelial cells in vitro: Studies on potassium (86Rb) influx and cellular proliferation. Clin Chim Acta 187:47–54.PubMedGoogle Scholar
  20. 20.
    Nguyen L, Ward WF, Ts’ao CH, Molteni A. 1994. Captopril inhibits proliferation of human lung fibroblasts in culture: A potential anti-fibrotic mechanism. Proc Soc Exp Biol Med 205:80–84.PubMedGoogle Scholar
  21. 21.
    Volpert OV, Ward WF, Lingen MW, Chester L, Solt B, Johnson MD, Molteni A, Polverini PJ, Bouck NP. 1996. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 98:671–679.PubMedGoogle Scholar
  22. 22.
    Cohen EP, Fish BL, Moulder JE. 1992. Treatment of radiation nephropathy with captopril. Radiat Res 132:346–350.PubMedGoogle Scholar
  23. 23.
    Ward WF, Molteni A, Ts’ao CH, Hinz JM. 1990. Captopril reduces collagen and mast cell accumulation in irradiated rat lung. Int J Radiat Oncol Biol Phys 19:1405–1409.PubMedGoogle Scholar
  24. 24.
    Ward WF, Lin PP, Wong PS, Behnia R, Jalali N. 1993. Radiation pneumonitis in rats and its modification by the angiotensin-converting enzyme inhibitor captopril evaluated by high-resolution computed tomography. Radiat Res 135:81–87.PubMedGoogle Scholar
  25. 25.
    Yarom R, Harper IS, Wynchank S, van Schalkwyk D, Madhoo J, Williams K, Salie R, Genade S, Lochner A. 1993. Effect of captopril on changes in rats’ hearts induced by long-term irradiation. Radiat Res 133:187–197.PubMedGoogle Scholar
  26. 26.
    Port CD, Ward WF. 1982. The ultrastructure of radiation injury in rat lung: Modification by D-penicillamine. Radiat Res 92:61–82.PubMedGoogle Scholar
  27. 27.
    Atkins FM, Friedman MM, Subba Rao PV, Metcalfe DD. 1985. Interactions between mast cells, fibroblasts and connective tissue components. Int Arch Allergy Appl Immunol 77:96–102.PubMedGoogle Scholar
  28. 28.
    Robbins MEC, Bonsib SM. 1995. Radiation nephropathy: A review. Scanning Microsc 9:535–560.PubMedGoogle Scholar
  29. 29.
    Moulder JE, Fish BL. 1989. Late toxicity of total body irradiation with bone marrow transplantation in a rat model. Int J Radiat Oncol Biol Phys 16:1501–1509.PubMedGoogle Scholar
  30. 30.
    Robbins MEC, Wooldridge MJA, Jaenke RS, Whitehouse E, Golding SJ, Rezvani M, Hopewell JW. 1991. A morphological study of radiation nephropathy in the pig. Radiat Res 126:317–327.PubMedGoogle Scholar
  31. 31.
    Cohen EP, Molteni A, Hill P, Fish BL, Ward WF, Moulder JE, Carone FA. 1996. Captopril preserves function and ultrastructure in experimental radiation nephropathy. Lab Invest 75:349–360.PubMedGoogle Scholar
  32. 32.
    Down JD, Berman AJ, Warhol M, Yeap B, Mauch P. 1990. Late complications following total-body irradiation and bone marrow rescue in mice: Predominance of glomerular nephropathy and hemolytic anemia. Int J Radiat Biol 57:551–565.PubMedGoogle Scholar
  33. 33.
    Luxton RW, Kunkler PB. 1964. Radiation nephritis. Acta Radiol 2:169–178.Google Scholar
  34. 34.
    Cohen EP, Lawton CA, Moulder JE. 1995. Bone marrow transplant nephropathy: Radiation nephritis revisited. Nephron 70:217–222.PubMedGoogle Scholar
  35. 35.
    Cohen EP, Lawton CA, Moulder JE, Becker CG, Ash RC. 1993. Clinical course of late-onset bone marrow transplant nephropathy. Nephron 64:626–635.PubMedGoogle Scholar
  36. 36.
    Lawton CA, Barber-Derus SW, Murray KJ, Cohen EP, Ash RC, Moulder JE. 1992. Influence of renal shielding on the incidence of late renal dysfunction associated with T-lymphocyte deplete bone marrow transplantation in adult patients. Int J Radiat Oncol Biol Phys 23:681–686.PubMedGoogle Scholar
  37. 37.
    Safwat A, Nielsen OS, Overgaard J. 1993. Is kidney the real dose-limiting organ after total body irradiation and bone marrow transplantation? Eur J Cancer 29A:929.PubMedGoogle Scholar
  38. 38.
    Juncos LI, Carrasco Duenas S, Cornejo JC, Broglia CA, Cejas H. 1993. Long-term enalapril and hydrochlorothiazide in radiation nephritis. Nephron 64:249–255.PubMedGoogle Scholar
  39. 39.
    Anderson S, Rennke HG, Brenner BM. 1986. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77:1993–2000.PubMedGoogle Scholar
  40. 39a.
    Moulder JE, Fish BL, Cohen E. 1997. Radiation nephropathy is treatable with an angiotensin converting enzyme inhibitor or an angiotensin II type-1 (AT1) receptor antagonist. Radiother Oncol, in press.Google Scholar
  41. 40.
    Ikoma M, Kawamura T, Kakinuma Y, Fogo A, Ichikawa I. 1991. Cause of variable therapeutic efficiency of angiotensin converting enzyme inhibitor on glomerular lesions. Kidney Int 40:195–202.PubMedGoogle Scholar
  42. 41.
    Moulder JE, Fish BL, Cohen EP. 1997. Non-continuous use of angiotensin converting enzyme inhibitors in the treatment of experimental bone marrow transplant nephropathy. Bone Marrow Transplant 19:729–735.PubMedGoogle Scholar
  43. 42.
    Cohen EP, Fish BL, Moulder JE. 1997. Successful brief captopril treatment in radiation nephropathy. J Lab Clin Med 129:536–547.PubMedGoogle Scholar
  44. 43.
    Johnston CI. 1995. Angiotensin receptor antagonists: Focus on losartan. Lancet 346:1403–1407.PubMedGoogle Scholar
  45. 44.
    Raij L, Azar S, Keane W. 1984. Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int 26:137–143.PubMedGoogle Scholar
  46. 45.
    Bachman S, Peters J, Engler E, Ganten D, Mullins J. 1992. Transgenic rats carrying the mouse renin gene — morphological characterization of a low-renin hypertension model. Kidney Int 41:24–36.Google Scholar
  47. 46.
    Ketteler M, Noble NA, Border WA. 1995. Transforming growth factor-β and angiotensin II: The missing link from glomerular hypernltration to glomerulosclerosis. Ann Rev Physiol 57:279–295.Google Scholar
  48. 47.
    Moncada S, Higgs EA. 1991. Endogenous nitric oxide: Physiology, pathology and clinical relevance. Eur J Clin Invest 21:361–374.PubMedGoogle Scholar
  49. 48.
    Cohen EP, Fish BL, Moulder JE. 1996. The role of nitric oxide in radiation nephropathy. Arch Physiol Biochem 104:200–206.PubMedGoogle Scholar
  50. 49.
    Moulder JE, Cohen EP, Fish BL, Hill P. 1993. Prophylaxis of bone marrow transplant nephropathy with captopril, an inhibitor of angiotensin-converting enzyme. Radiat Res 136:404–407.PubMedGoogle Scholar
  51. 50.
    Michalowski AS. 1992. Post-irradiation modification of normal-tissue injury: Lessons from the clinic. Brit J Radiol Supplement 24:183–186.Google Scholar
  52. 51.
    Geraci JP, Mariano MS, Jackson KL, Taylor DA, Still ER. 1992. Effects of dexamethasone on late radiation injury following partial-body and local organ exposures. Radiat Res 129:61–70.PubMedGoogle Scholar
  53. 52.
    Geraci JP, Mariano MS, Jackson KL. 1993. Amelioration of radiation nephropathy in rats by dexamethasone treatment after irradiation. Radiat Res 134:86–93.PubMedGoogle Scholar
  54. 53.
    Geraci JP, Sun MC, Mariano MS. 1995. Amelioration of radiation nephropathy in rats by postirradiation treatment with dexamethasone and/or captopril. Radiat Res 143:58–68.PubMedGoogle Scholar
  55. 54.
    Verheij M, Stewart FA, Oussoren Y, Weening JJ, Dewit L. 1995. Amelioration of radiation nephropathy by acetylsalicylic acid. Int J Radiat Biol 67:587–596.PubMedGoogle Scholar
  56. 55.
    Blomstrand C, Johansson B, Rosengren B. 1975. Dexamethasone effect on blood brain-barrier damage caused by acute hypertension in X-irradiated rabbits. Acta Neurol Scand 52:331–334.PubMedGoogle Scholar
  57. 56.
    Martins AN, Severance RE, Henry JM, Doyle TF. 1979. Experimental delayed radiation necrosis of the brain. Part 1: Effect of early dexamethasone treatment. J Neurosurg 51:587–596.PubMedGoogle Scholar
  58. 57.
    Halpern J, Kishel SP, Park J, Tsukada Y, Johnson RJR, Ambrus JL. 1984. Radiation induced brain edema in primates, studied with sequential brain CAT scanning and histopathology. Protective effect of sodium meclofenamate. A preliminary report. Res Commun Chem Pathol Pharmacol 45:463–470.PubMedGoogle Scholar
  59. 58.
    Delattre JY, Rosenblum MK, Thaler HT, Mandell L, Shapiro WR, Posner JB. 1988. A model of radiation myelopathy in the rat. Pathology, regional capillary permeability changes and treatment with dexamethasone. Brain 111:1319–1336.PubMedGoogle Scholar
  60. 59.
    Geraci JP, Mariano MS, Jackson KL. 1993. Effect of adrenalectomy on the latency of radiation myelopathy in rats. Radiat Res 134:179–186.PubMedGoogle Scholar
  61. 60.
    Brown RF. 1956. Effect of cortisone on the radiation reaction of the rat lung. Am J Roentgenol 75:796–806.Google Scholar
  62. 61.
    Berdjis CC, Brown RF. 1957. Histopathology of the effect of cortisone on the irradiated rat lung. Diseases Chest 32:481–492.Google Scholar
  63. 62.
    Moss WT, Haddy FJ, Sweany SK. 1960. Some factors altering the sensitivity of acute radiation pneumonitis: Variation with cortisone, heparin, and antibiotics. Radiology 75:50–54.PubMedGoogle Scholar
  64. 63.
    Phillips TL, Wharam MD, Margolis LW. 1975. Modification of radiation injury to normal tissues by chemotherapeutic agents. Cancer 35: 1678–1684.PubMedGoogle Scholar
  65. 64.
    Gross NJ, Narine KR, Wade R. 1988. Protective effect of corticosteroids on radiation pneumonitis in mice. Radiat Res 113:112–119.PubMedGoogle Scholar
  66. 65.
    Gross NJ. 1980. Radiation pneumonitis in mice. Some effects of corticosteroids on mortality and pulmonary physiology. J Clin Invest 66:504–510.PubMedGoogle Scholar
  67. 66.
    Evans ML, Graham MM, Mahler PA, Rasey JS. 1987. Use of steroids to suppress vascular response to radiation. Int J Radiat Oncol Biol Phys 13:563–567.PubMedGoogle Scholar
  68. 67.
    Graham MM, Evans ML, Dahlen DD, Mahler PA, Rasey JS. 1990. Pharmacological alteration of the lung vascular response to radiation. Int J Radiat Oncol Biol Phys 19:329–339.PubMedGoogle Scholar
  69. 68.
    Peterson LM, Evans ML, Graham MM, Eary JF, Dahlen DD. 1992. Vascular response to radiation injury in the rat lung. Radiat Res 129: 139–148.PubMedGoogle Scholar
  70. 69.
    Ward HE, Kemsley L, Davies L, Holecek M, Berend N. 1993. The effect of steroids on radiation-induced lung disease in the rat. Radiat Res 136:22–28.PubMedGoogle Scholar
  71. 70.
    Loyd JE, Bolds JM, Wickersham N, Malcolm AW, Brigham KL. 1988. Corticosteroids prevent acute lung dysfunction caused by thoracic irradiation in unanesthetized sheep. Am Rev Respir Dis 138:1227–1233.PubMedGoogle Scholar
  72. 71.
    Gross NJ, Holloway NO, Narine KR. 1991. Effects of some nonsteroidal anti-inflammatory agents on experimental radiation pneumonitis. Radiat Res 127:317–324.PubMedGoogle Scholar
  73. 72.
    Orfanos SE, Chen XL, Burch SE, Ryan JW, Chung AY, Catravas JD. 1994. Radiation-induced early pulmonary endothelial ectoen-zyme dysfunction in vivo: Effect of indometh-acin. Toxicol Appl Pharmacol 124:112–122.PubMedGoogle Scholar
  74. 73.
    Reeves WC, Stryker JA, Abt AB, Chung CK, Whitesell L, Zelis R. 1980. Early corticosteroid administration in experimental radiation-induced heart disease. Radiology 134:533–535.PubMedGoogle Scholar
  75. 74.
    Reeves WC, Cunningham D, Schwiter EJ, Abt A, Skarlatos S, Wood MA, Whitesell L. 1982. Myocardial hydroxyproline reduced by early administration of methylprednisolone or ibu-profen to rabbits with radiation-induced heart disease. Circulation 65:924–927.PubMedGoogle Scholar
  76. 75.
    Schleimer RP. 1993. An overview of glucocorticoid anti-inflammatory actions. J Clin Pharmacol 45(Suppl. 1):S3–S7.Google Scholar
  77. 76.
    Ts’ao CH, Ward WF, Port CD. 1983. Radiation injury in rat lung. I. Prostacyclin (PGI2) production, arterial perfusion, and ultrastructure. Radiat Res 96:284–293.PubMedGoogle Scholar
  78. 77.
    Ziboh VA, Mallia C, Morhart E, Taylor JR. 1982. Induced biosynthesis of cutaneous prostaglandins by ionizing radiation. Proc Soc Exp Biol Med 169:386–391.PubMedGoogle Scholar
  79. 78.
    Schneidkraut MJ, Kot PA, Ramwell PW, Rose JC. 1984. Thromboxane and prostacyclin synthesis following whole body irradiation in rats. J Appl Physiol 57:833–838.PubMedGoogle Scholar
  80. 79.
    Siegal T, Pfeffer MR. 1995. Radiation-induced changes in the profile of spinal cord serotonin, prostaglandin synthesis, and vascular permeability. Int J Radiat Oncol Biol Phys 31:57–64.PubMedGoogle Scholar
  81. 80.
    Hopewell JW, Robbins MEC, van den Aardweg GJMJ, Morris GM, Ross GA, Whitehouse E, Horrobin DF, Scott CA. 1993. The modulation of radiation-induced damage to pig skin by essential fatty acids. Br J Cancer 68:1–7.PubMedGoogle Scholar
  82. 81.
    Hopewell JW, van den Aardweg GJMJ, Morris GM, Rezvani M, Robbins MEC, Ross GA, Whitehouse EM, Scott CA, Horrobin DF. 1994. Amelioration of both early and late radiation-induced damage to pig skin by essential fatty acids. Int J Radiat Oncol Biol Phys 30:1119–1125.PubMedGoogle Scholar
  83. 82.
    Kirtland SJ. 1988. Prostaglandin E1: A review. Prostaglandins Leukot Essent Fatty Acids 32:165–174.PubMedGoogle Scholar
  84. 83.
    Manku MS, Morse-Fisher N, Horrobin DF. 1988. Changes in human plasma essential fatty acid levels as a result of administration of linoleic acid and gamma-linolenic acid. Eur J Clin Nutr 42:55–60.PubMedGoogle Scholar
  85. 84.
    Hopewell JW, van den Aardweg GJMJ, Morris GM, Rezvani M, Robbins MEC, Ross GA, Whitehouse EM. 1994. Unsaturated lipids as modulators of radiation damage in normal tissues. In Horrobin DF, ed. New Approaches to Cancer Treatment. London: Churchill Communications Europe, pp. 88–106.Google Scholar
  86. 85.
    Hopewell JW, van den Aardweg GJMJ. 1988. Radiobiological studies with pig skin. Int J Radiat Oncol Biol Phys 14:1047–1050.PubMedGoogle Scholar
  87. 86.
    El-Agamawi AY, Hopewell JW, Plowman PN, Rezvani M, Wilding D. 1996. Modulation of normal tissue responses to radiation. Br J Radiol 39:374–375.Google Scholar
  88. 87.
    Hall EJ. 1994. Molecular biology in radiation therapy: The potential impact of recombinant technology on clinical practice. Int J Radiat Oncol Biol Phys 30:1019–1028.PubMedGoogle Scholar
  89. 88.
    Horrobin DF. 1990. Essential fatty acids, lipid peroxidation, and cancer. In Horrobin DF, ed. Omega-6 Essential Fatty Acids: Pathophysiology and Roles in Clinical Medicine. New York: Wiley-Liss, pp. 351–378.Google Scholar
  90. 89.
    Strieter RM, Remick DG, Ward PA, Spengler RN, Lynch JP, Larrick J, Kunkel SL. 1988. Cellular and molecular regulation of tumor necrosis factor-α production by pentoxifylline. Biochem Biophys Res Commun 155:1230–1236.PubMedGoogle Scholar
  91. 90.
    Ward WF, Kim YT, Molteni A, Ts’ao CH, Hinz JM. 1992. Pentoxifylline does not spare acute radiation reactions in rat lung and skin. Radiat Res 129:107–111.PubMedGoogle Scholar
  92. 91.
    Koh WJ, Stelzer KJ, Peterson LM, Staker BL, Ward WF, Russell KJ, Griffin TW. 1995. Effect of pentoxifylline on radiation-induced lung and skin toxicity in rats. Int J Radiat Oncol Biol Phys 31:71–77.PubMedGoogle Scholar
  93. 92.
    Hong J, Chiang C, Campbell IL, Sun J, Withers HR, McBride WH. 1995. Induction of acute phase gene expression by brain irradiation. Int J Radiat Oncol Biol Phys 33:619–626.PubMedGoogle Scholar
  94. 93.
    Kim SH, Khil MS, Ryu S, Kim JH. 1993. Enhancement of radiation response of human carcinoma cells in culture by pentoxifylline. Int J Radiat Oncol Biol Phys 25:61–65.PubMedGoogle Scholar
  95. 94.
    Fan S, Smith ML, Rivet DJ, Duba D, Zhan Q, Kohn KW, Fornace AJ, O’Connor PM. 1995. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55:1649–1654.PubMedGoogle Scholar
  96. 95.
    Lee I, Levitt SH, Song CW. 1993. Improved tumor oxygenation and radiosensitization by combination with nicotinamide and pentoxifylline. Int J Radiat Biol 64:237–244.PubMedGoogle Scholar
  97. 96.
    Lee I, Boucher Y, Demhartner TJ, Jain RK. 1994. Changes in tumor blood flow, oxygenation and interstitial pressure induced by pentoxifylline. Br J Cancer 69:492–496.PubMedGoogle Scholar
  98. 97.
    Dion MW, Hussey DH, Doornbos JF, Vigliotti AP, Wen BC, Anderson B. 1990. Preliminary results of a pilot study of pentoxifylline in the treatment of late radiation soft tissue necrosis. Int J Radiat Oncol Biol Phys 19:401–407.PubMedGoogle Scholar
  99. 98.
    Bianco JA, Appelbaum FR, Nemunaitis J, Almgren J, Andrews F, Kettner P, Shields A, Singer JW. 1991. Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood 78:1205–1211.PubMedGoogle Scholar
  100. 99.
    Delanian S, Baillet F, Huart J, Lefaix JL, Maulard C, Housset M. 1994. Successful treatment of radiation-induced fibrosis using liposomal Cu/Zn Superoxide dismutase: Clinical trial. Radiother Oncol 32:12–20.PubMedGoogle Scholar
  101. 100.
    Malaker K, Das RM. 1988. The effect of Superoxide dismutase on the pathogenesis of radiation-induced pulmonary damage in the rat. Pharmacol Ther 39:327–330.PubMedGoogle Scholar
  102. 101.
    Lefaix JL, Delanian S, Leplat JJ, Tricaud Y, Martin M, Nimrod A, Baillet F, Daburon F. 1996. Successful treatment of radiation-induced fibrosis using Cu/Zn-SOD and Mn-SOD: An experimental study. Int J Radiat Oncol Biol Phys 35:305–312.PubMedGoogle Scholar
  103. 102.
    McAnulty RJ, Laurent GJ. 1995. Pathogenesis of lung fibrosis and potential new therapeutic strategies. Exp Nephrol 3:96–107.PubMedGoogle Scholar
  104. 103.
    Percarpio B, Fischer JJ. 1976. Beta-aminopropionitrile as a radiation reaction preventive agent. Radiology 121:737–740.PubMedGoogle Scholar
  105. 104.
    Lubec B, Rokitansky A, Hayde M, Aufricht C, Wagner U, Mallinger WR, Höger H, Lubec G. 1994. Thiaproline reduces glomerular basement membrane thickness and collagen accumulation in the db/db mouse. Nephron 66:333–336.PubMedGoogle Scholar
  106. 105.
    Iyer SN, Wild JS, Schiedt MJ, Hyde DM, Margolin SB, Giri SN. 1995. Dietary intake of pirfenidone ameliorates bleomycin-induced lung fibrosis in hamsters. J Lab Clin Med 125:779–785.PubMedGoogle Scholar
  107. 106.
    Barcellos-Hoff MH, Derynck R, Tsang ML, Weatherbee JA. 1994. Transforming growth factor-β activation in irradiated murine mammary gland. J Clin Invest 93:892–899.PubMedGoogle Scholar
  108. 107.
    Border WA, Noble NA. 1994. Transforming growth factor-β in glomerular injury. Exp Nephrol 2:13–17.PubMedGoogle Scholar
  109. 108.
    Isaka Y, Brees DK, Ikegaya K, Kaneda Y, Imau E, Noble NA, Border WA. 1996. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nature Med 2:418–423.PubMedGoogle Scholar
  110. 109.
    Yoon SC, Park JM, Jang HS, Shinn KS, Bahk YW. 1994. Radioprotective effect of captopril on the mouse jejunal mucosa. Int J Radiat Oncol Biol Phys 30:873–878.PubMedGoogle Scholar
  111. 110.
    Moulder JE, Fish BL. 1997. Angiotensin converting enzyme captopril does not prevent acute gastrointestinal radiation damage in the rat. Radiat Oncol Invest 5:50–53.Google Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • John E. Moulder
  • Michael E. C. Robbins
  • Eric P. Cohen
  • John W. Hopewell
  • William F. Ward

There are no affiliations available

Personalised recommendations